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Objectives: The purpose of the budget impact analysis (BIA) was to estimate 
financial consequences of deferasirox (DSX) reimbursement within the health care 
treatment programme (HTP) on the budget of the National Health Fund (NHF) in 
Poland. MethOds: BIA was performed for a 2-year time horizon (July 2012 - June 
2014) from the Polish public payer perspective. The target population qualified to the 
HTP programme were children and adolescents (age ≤ 18 years) with iron overload 
due to frequent blood transfusions. The population was estimated on the basis of 
medical expert opinion. Two scenarios were compared: the “existing scenario” – 
without reimbursement of DSX (only standard of care with deferoxamine (DFO) 
was available) and the “new scenario” – DSX reimbursed as part of HTP. In the 
analysis, only direct medical costs were included: costs of drugs and their admin-
istration, costs of monitoring and costs of blood transfusions. It was assumed that 
the cost of deferoxamine was included in the cost of hospitalization procedures 
related to chelation therapy. Due to the lack of available data on adverse events 
(AE) incidence during therapy with deferasirox or deferoxamine, the costs of AE’s 
treatment were not considered. The calculations were performed in Microsoft Office 
Excel. Results: NHF annual expenditures related to the introduction of deferasirox 
reimbursement will increase by PLN 454 thousand in the first year and by PLN 
434 thousand in the second year of reimbursement compared with the “existing 
scenario.” cOnclusiOns: The positive reimbursement decision for DSX enables 
patients with iron overload access to safe and effective therapy. Deferasirox therapy 
will allow young patients to go back to normal functioning in their families and in 
society. The positive reimbursement decision will also contribute to improving the 
quality of life, self-esteem and emotional state of the patients.
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Objectives: To undertake a comparative analysis of 2 methodologies of inten-
sive treatment (IT) , precisely: IT without NS and IT taking into account NS han-
dling. MethOds: Pharmacoeconomic analysis “budget impact” was provided. Only 
direct costs were taken into account: expenses for drug therapy, hospitalization 
(intensive care unit and medical division) and late complications (pneumonia, sepsis, 
catheter and wound infection) treatment. Effectiveness data was taken from Russian 
clinical trial: Popov T.S., Shestopalov A.E., Tsvetkov D.S., Nechaev D.S., Kuz’min M.A. 
Nutrition Day in intensive care units of the Russian Federation. National association 
of parenteral and enteral nutrition – Moscow (Russia), 2011. Four types of NS were 
compared: IT without NS; IT + enteral nutrition (EN); IT + parenteral nutrition (PN) 
and IT + combined nutrition (CN). Results: When carrying out comparative phar-
macoeconomic study all calculations were made for 3 groups of patients depending 
on their health condition: lightly-severe, moderately severe and severe. According to 
the results of calculations transfer of patients from IT without NS to IT carrying out 
NS leads to reduction of total expenses, therefore economy of money for the state. 
Independent from patient health condition – the greatest economy of money arises 
when EN is used during IT. Further on degree of expressiveness of positive economic 
effect there is PN and the least NS economic type is CN. cOnclusiOns: The results 
received during the study were analyzed and the rating of NS types, which were taking 
part in the research, from the point of view of their clinical efficiency and economic 
effectiveness for the state budget, was made.
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Objectives: To demonstrate the economic impact of using NovoSeven compared to 
Feiba for the initial treatment of mild to moderate bleeding episodes in patients with 
haemophilia A with inhibitors. MethOds: A budget impact model was developed 
based on a previous economic evaluation to calculate the annual budget impact 
and the treatment cost per episode according to the different treatment strategies. 
The model presents the costs of the strategies to treat a mild to moderate bleeding 
episode with up to three lines of treatment, in which the impact parameters are the 
weight of the patient, the dose, the efficacy and the costs of medication and admin-
istration. Three treatment strategies were used: strategy 1: NovoSeven - NovoSeven 
- NovoSeven, strategy 2: Feiba - NovoSeven - NovoSeven and strategy 3: Feiba - Feiba - 
NovoSeven. Costs per episode and annual costs were calculated based on local input 
data on costs and resources and the perspective used was of the Spanish National 
Health Service (NHS). Results: Total costs per patient for one bleeding episode 
were € 10,253, € 11,852 and € 12,042 for strategies 1, 2 and 3, respectively. Lower total 
costs per patient with NovoSeven are due to a reduced need for further treatment 
and associated hospitalisation. Only using NovoSeven saves € 23,985 compared to 
strategy 2 and € 26,842 compared to strategy 3 annually. cOnclusiOns: The use 
of NovoSeven in all three lines of treatment in patients with in haemophilia A 
compared to using Feiba in the first line of treatment and in the first and second 
line of treatment saves € 1,599 and € 1,789 respectively per bleeding episode. This is 
mainly due to reduced need for further treatment and associated hospitalisation 
with NovoSeven. Annual cost savings using only NovoSeven are the consequence 
of lower drug cost and higher treatment efficacy with NovoSeven.
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Avoidance of administration costs for infused treatments could offset the higher 
acquisition cost for deferasirox. Additional data is required to confirm efficacy of 
other treatments in patients with NTDT.
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Objectives: Neuropathic pain (NP) is a common disorder which can be chronic, 
severe, and disabling and is associated with reductions in quality of life and consid-
erable costs. Current first-line treatments for NP include tricyclic antidepressants 
and anti-convulsants. QUTENZA® is a cutaneous patch that allows rapid dermal 
delivery of capsaicin directly to the source of pain. The objective of this analysis 
is to estimate the burden of NP, current treatment costs and the budget impact of 
introducing QUTENZA® for the treatment of peripheral NP in non-diabetic adults 
in Sweden. MethOds: We constructed a budget impact calculator to estimate the 
impact of introducing QUTENZA® for 100 people in Sweden. Drug costs for each 
management strategy are annual costs, based on estimated market shares, and 
range from SEK 231 to SEK 5,806 (with SEK 3,909 for QUTENZA®). We assumed a 50% 
uptake of QUTENZA® and a 50% reduction in the use of concomitant medication in 
the model, based on evidence from real-world data. Results: For a NP population 
of n= 100, the cost of current prescribing was estimated at SEK 1.00 million. The cost 
of alternative prescribing including QUTENZA® was estimated at SEK 1.01 million. 
The annual cost of treating a patient with QUTENZA® was estimated as SEK 11,941. 
The estimated cumulative budget impact by year (for 100 patients, with the market 
share rising from 10% in Year 1 to 100% in Year 5) ranged from SEK 9,664 in Year 1 to 
SEK 67,949 in Year 5. cOnclusiOns: The introduction of QUTENZA® results in a 
budget impact of SEK 67,949 for 100 patients over 5 years. This represents a minimal 
additional expenditure and could be considered good value for money given the 
added benefits for patients with NP in Sweden.
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Objectives: To identify the dominant scheme of inhibitor hemophilia bypassing 
agents therapy (comparing three regimens: Eptacog alfa monotherapy, combination 
therapy «Eptacog alfa + AICC» and «AICC + Eptacog alfa»). MethOds: Based on 
the crossover clinical research FENOC (Jan Astermark, Sharyne M., Donfield, 2007) 
the annual cost of treatment by bypassing agents in mild, moderate, severe and 
life-threatening bleeding is estimated. The analysis of the direct and indirect costs 
is conducted. Direct costs include the cost of bypassing agents therapy, the cost of 
emergency medical care, the cost of inpatient and outpatient treatment. Indirect 
costs include cost of patient’s disability, GDP losses caused by mortality and dis-
ability, and sick-pay. Value of bypassing agents on demand therapy in three dosing 
schemes is identified: monotherapy Eptacog alfa (there is no alternative treatment), 
«Eptacog alfa + AICC» (after the first episode of bleeding no response patients to 
treatment from Eptacog alfa to AICC transferred) and «AICC + Eptacog alfa» (after 
the first episode of bleeding no response patients to treatment from AICC to Eptacog 
alfa transferred). Results: Based on the clinical study FENOC, indicated that there 
is no significant difference in efficacy AICC and Eptacog alfa therapy in patients 
susceptible to this treatment. An analysis of the direct and indirect costs shows that 
the costs of the annual course of treatment of 142 patients in Russia are 66 mil EUR, 
60,7 mil EUR and 53,1 mil EUR for treatments Eptacog alfa monotherapy, «Eptacog 
alfa + AICC» and «AICC + Eptacog alfa» schemes respectively. cOnclusiOns: It is 
determined that the regimen «AICC + Eptacog alfa», will reduce reduces costs rela-
tive to the current treatment regimen for 12,9 mil EUR (19,54%) or provide addition-
ally treat of 34 patients of this disease.
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Objectives: To evaluate the economic impact on Italian NHS of using sugam-
madex within anaesthetic departments instead of neostigmine. MethOds: The 
number of procedures using neuromuscular blockings agents (NMBA) potentially 
eligible for sugammadex was elaborated by hospital discharge data available in 
Italy for the year 2010. Reduction in postoperative residual curarisation (PORC) 
rate and saved time allocated to extra procedures were taken from two recent 
meta-analyses. Costs considered in the analysis were drugs acquisition costs 
(sugammadex and neostigmine) and PORC management costs. Results: Overall 
annual costs of sugammadex and neostigmine usage result about 34.5 and 31.6 
Million Euro, respectively. Sugammadex prevents 99% of PORC episodes on 428,995 
procedures; this is associated with savings of more than 30 Million Euro. Also the 
saved time in surgery procedures due to sugammadex results in an annual savings 
of 154,867 (36.1%) hours that could be used for further procedures. cOnclusiOns: 
Sugammadex radically reduces PORC episodes during post-operative and it allows 
for shorter operating room occupation.
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